Zobrazeno 81 - 90
of 565
pro vyhledávání: '"Kathleen I. Pritchard"'
Autor:
Denis Larsimont, Daniel Rea, Alison F. Munro, Janet A. Dunn, Carlos Caldas, Frances P. O'Malley, Christopher C. McConkey, Angelo Di Leo, Christine Desmedt, David Cameron, Helena M. Earl, Lois E. Shepherd, Maj-Britt Jensen, Christopher J. Poole, Bent Ejlertsen, John M. S. Bartlett, Fatima Cardoso, Kathleen I. Pritchard, Chris J. Twelves
Publikováno v:
Journal of Clinical Oncology. 33:1680-1687
Purpose Evidence supporting the clinical utility of predictive biomarkers of anthracycline activity is weak, with a recent meta-analysis failing to provide strong evidence for either HER2 or TOP2A. Having previously shown that duplication of chromoso
Autor:
Hong-Anh Tu, Murray Krahn, Kathleen I. Pritchard, Jordan J. Feld, William Wong, Lisa K. Hicks, Kelvin K. W. Chan
Publikováno v:
Breast Cancer Research and Treatment. 151:639-652
Most patients with hepatitis B virus (HBV) have no symptoms, and many are unaware of the infection. However, HBV can reactivate with immunosuppression; chemotherapy causes reactivation in 22 % of hepatitis B surface antigen-positive patients. HBV rea
Autor:
Rustem Khasanov, Judith-Anne W. Chapman, Frances M. Boyle, Anne P. Connor, Miguel Martin, Arnd Nusch, Karen A. Gelmon, Timothy J. Whelan, Alexey Manikhas, Katia Tonkin, David Huntsman, Kathleen I. Pritchard, Dora Nomikos, Hirofumi Mukai, Julie Lemieux, Susan Ellard, Sergei Tjulandin, Robert E. Coleman, Sergio Santillana, Bella Kaufman, Shulamith Rizel, Susan Dent, Angelo Di Leo, Lee S. Schwartzberg, Wendy R. Parulekar, Lois E. Shepherd, Samuel Aparicio
Publikováno v:
Europe PubMed Central
Purpose The efficacy of lapatinib versus trastuzumab combined with taxanes in the first-line setting of human epidermal growth factor receptor 2 (HER2) –positive metastatic breast cancer (BC) is unknown. Patients and Methods The MA.31 trial compare
Autor:
Chris Twelves, Fouad Yousif, John M. S. Bartlett, Melanie Spears, Nicola Lyttle, Lois E. Shepherd, Mark Levine, Alison F. Munro, Kathleen I. Pritchard
Publikováno v:
Cancer Research. 75:P2-05
Background: Chromosome instability (CIN) in solid tumours is associated with poor prognosis and results in numerical and structural chromosomal aberrations. Recent evidence from both the BR9601 and MA.5 trials has demonstrated CEP17 duplication as a
Autor:
Ravi Ramjeesingh, Wendy R. Parulekar, Liting Zhu, Margot J. Burnell, Lois E. Shepherd, Vivien H.C. Bramwell, Joseph L. Pater, Bingshu E. Chen, Kathleen I. Pritchard
Publikováno v:
Cancer Research. 75:P3-09
Background: For early high risk breast cancer, adjuvant chemotherapy following definitive surgery is a current standard of care. However, the optimal time to commencement of therapy has not been well established. We evaluated the association between
Autor:
Miguel Martin, Mark Levine, Lourdes Calvo, Amparo Ruiz, Stephen Chia, Rosalia Caballero, Matthew J. Ellis, Lois E. Shepherd, Álvaro Rodríguez-Lescure, Maggie C.U. Cheang, Kathleen I. Pritchard, Vivien H.C. Bramwell, D. Voduc, Dongsheng Tu, Emilio Alba, Angelo Di Leo, Philip S. Bernard, Lisa A. Carey, Eva Carrasco, Aleix Prat, Torsten O. Nielsen, Joel S. Parker, Charles M. Perou, Manuel Ruiz-Borrego
Publikováno v:
Oncologist
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-FISABIO. Repositorio Institucional de Producción Científica
instname
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-FISABIO. Repositorio Institucional de Producción Científica
instname
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Purpose. To determine intrinsic breast cancer subtypes represented within categories defined by quantitative hormone receptor (HR) and HER2 expression. Methods. We merged 1,557 cases from three randomized phase III trials into a single data set. Thes
Autor:
Edith A. Perez, Elena Tsvetkova, Ana Elisa Lohmann, Judy Anne W. Chapman, Margot J. Burnell, Haji Chalchal, Lei Han, Theodore A. Vandenberg, Mark Levine, Lois E. Shepherd, Ravinder Sawhney, Pamela J. Goodwin, Kathleen I. Pritchard, Hope S. Rugo, Patti O'Brien, Kathy S. Albain, Karen A. Gelmon
Publikováno v:
Breast Cancer Research and Treatment. 150:605-611
Low vitamin D levels have been associated with poor breast cancer outcomes in observational studies. We examined the association of vitamin D blood levels with relapse-free survival (RFS), breast cancer-specific survival (BCSS), and overall survival
Autor:
Frances M, Boyle, Ian E, Smith, Joyce, O'Shaughnessy, Bent, Ejlertsen, Aman U, Buzdar, Pierre, Fumoleau, William, Gradishar, Miguel, Martin, Beverly, Moy, Martine, Piccart-Gebhart, Kathleen I, Pritchard, Deborah, Lindquist, Mayur, Amonkar, Yingjie, Huang, Erica, Rappold, Lisa S, Williams, Jing, Wang-Silvanto, Tomomi, Kaneko, Dianne M, Finkelstein, Paul E, Goss, Lindquist
Publikováno v:
European Journal of Cancer. 51:685-696
To evaluate health related quality of life (HRQOL) in TEACH, a phase III randomized placebo controlled trial of 12 months of adjuvant lapatinib in HER2 positive (HER2+) early breast cancer which demonstrated marginal benefit in disease-free survival.
Autor:
Daniel F. Hayes, Julie Gralow, Lisa A. Carey, EM Beasley, S Shak, Kunbin Qu, JN Ingle, Kathleen I. Pritchard, Robert B. Livingston, Gabriel N. Hortobagyi, F Collin, Audrey Goddard, CK Osborne, Peter M. Ravdin, W. Barlow, KS Albain, Diana B. Cherbavaz, Crager, Amy P. Sing, MC Liu, FL Baehner, Nancy E. Davidson, James M. Rae, Debu Tripathy, J-H Jeong
Publikováno v:
Cancer Research. 76:P5-07
BACKGROUND: We previously reported that low 21 gene Recurrence Scores (RS) identify patients with ER-positive, lymph node-positive breast cancer who may not benefit from anthracycline-based adjuvant chemotherapy added to tamoxifen (SWOG-8814A NCI cor
Autor:
Ian Bradbury, Henry L. Gomez, István Láng, B H Xu, Antonio C. Wolff, Kathleen I. Pritchard, Amir Sonnenblick, Michael Untch, E. A. Perez, M.J. Piccart, Yingjie Huang, I. E. Smith, Frances M. Boyle, Fergus Daly, E. de Azambuja, Dominique Agbor-Tarh, Christian Jackisch, Hatem A. Azim, Amylou C. Dueck
Publikováno v:
Cancer Research. 76:PD5-07
Background: We have previously shown in a phase III neoadjuvant trial that early development of lapatinib-induced rash (i.e. within 6 weeks after lapatinib initiation) is independently associated with a higher chance of obtaining a pathological compl